FDA MedWatch - LeadCare II, LeadCare Plus, and LeadCare Ultra Blood Lead Tests by Magellan Diagnostics:

Class I Recall - Due to Risk of Falsely Low Results

If your email program has trouble displaying this email, view as a webpage. MedWatch - The FDA Safety Information and Adverse Event Reporting Program TOPIC: LeadCare II, LeadCare Plus, and LeadCare Ultra Blood Lead Tests by Magellan Diagnostics: Class I Recall - Due to Risk of Falsely Low Results AUDIENCE: Patient, Health Professional, Risk Manager, Medical Technology, Laboratory ISSUE: Magellan Diagnostics, has expanded its recall of LeadCare II, LeadCare Plus, and LeadCare Ultra Blood Lead Tests due to a significant risk of falsely low results. The FDA has significant concerns that the performance of the test may provide falsely low results and may lead to health risks in special populations such as young children and pregnant individuals. A pregnant or lactating individual's exposure to lead is concerning because it not only may cause health problems for the parent but can result in lead exposure to the developing baby. Obtaining falsely low results may lead to patient harm including delayed puberty, reduced postnatal growth, decreased IQ, and inattention and behavior problems in children. For more information about this recall, click on the red button "Read Recall" below. BACKGROUND: The LeadCare II, LeadCare Plus, and LeadCare Ultra Blood Lead Tests are used to find out a person's blood lead level. RECOMMENDATIONS: On May 28, 2021, Magellan notified distributors through phone calls and on June 7, 2021 sent customers an Urgent Medical Device Recall letter requesting product removal of specific lots.  On June 23, 2021, Magellan notified customers by phone the recall has been expanded to include additional lots. On August 31, 2021, Magellan began notifying customers by email and distributors by phone that the recall was expanded a second time to include the following LeadCare II lots of test kits, which includes lots previously reported as unaffected by this recall: sublots 2012M-08, 2012M-09, 2012M-10, 2012M-11, 2012M-12, 2012M-13, and 2012M-14; and full lots 2018M; 2102M; 2109M; 2110M; 2111M; 2112M; 2113M; 2114M; 2115M; and 7114M. Customers and distributors are instructed to also take the following actions: Customers: Discontinue use of all test kit lots identified as part of the recall and quarantine remaining inventory. Laboratories should evaluate patient test results that were generated with the impacted lots. Confirm suspect results with an alternative lead testing option, such as those using inductively coupled plasma mass spectrometry or graphite furnace atomic absorption spectroscopy at a high complexity, CLIA-certified, reference laboratory. Refer to retesting recommendations from the CDC. Promptly complete and return the Customer Notification Form in the Urgent Medical Device Recall letter. Complete this form even if you have no remaining inventory. Be aware, product will be replaced based on availability; replacement product is NOT currently available. Distributors: Stop distribution of LeadCare blood lead test kits identified as part of the recall; review current inventory and quarantine any remaining stock. Health professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program: Complete and submit the report online. Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on form, or submit by fax to 1-800-FDA-0178.

Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA